Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
PLoS One. 2021 Jul 19;16(7):e0254863. doi: 10.1371/journal.pone.0254863. eCollection 2021.
In 2012, recommendations for universal tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination during pregnancy were released. Our objective was to determine if Tdap, influenza, and pneumococcal vaccine uptake during pregnancy changed after the release of the guidelines, and identify factors associated with receiving the Tdap and influenza vaccine after 2012.
We conducted a retrospective cohort study on pregnant individuals who initiated prenatal care before 20 weeks' gestation between 11/2011-11/2012 ("pre-guideline") and 12/2012-12/2015 ("post-guideline"). Vaccine uptake dates were abstracted from medical records. The pre and post-guideline cohorts were compared to determine if Tdap vaccine uptake and timing improved after the new Tdap guidelines. We additionally examined influenza and pneumococcal vaccine uptake before and after guidelines. Factors associated with receipt of the Tdap and influenza vaccine during pregnancy in the post-guideline cohort were evaluated using multivariable logistic regression models.
Of 2,294 eligible individuals, 1,610 (70.2%) received care in the post-guideline cohort. Among the pre-guideline cohort, 47.4% received Tdap, whereas Tdap uptake increased to 86.1% after the guidelines (p<0.001). Similarly, receiving the Tdap vaccine between the recommended time of 27-36 weeks gestational age improved from 52.5% to 91.8% after the guidelines (p<0.001). Vaccine frequency for influenza improved significantly from 61.2% to 72.0% (p<0.001), while frequency for pneumococcus were low and unchanged. An increased number of prenatal visits was associated with receiving the Tdap and influenza vaccines during pregnancy (respective, aOR 1.09 95% CI 1.05-1.13; aOR 1.50 95% CI 1.17-1.94). Non-Hispanic Black individuals were less likely to receive both the Tdap and influenza vaccines during pregnancy compared to non-Hispanic White individuals (respective, aOR 0.51 95% CI 0.33-0.80; aOR 0.68 95% CI 0.48-0.97).
Receipt and timing of Tdap vaccine improved after implementation of the 2012 ACIP guidelines. Receipt of influenza vaccine uptake also improved during the study period, while uptake of the pneumococcal vaccine remained low. Significant racial disparities exist in receipt of Tdap and influenza vaccine during pregnancy.
2012 年,发布了关于孕妇普遍接种破伤风类毒素、白喉类毒素和无细胞百日咳(Tdap)疫苗的建议。我们的目的是确定在指南发布后,孕妇接种 Tdap、流感和肺炎球菌疫苗的情况是否有所改变,并确定 2012 年后与接受 Tdap 和流感疫苗相关的因素。
我们对 2011 年 11 月至 2012 年 11 月(“前指南”)和 2012 年 12 月至 2015 年 12 月(“后指南”)期间在 20 周妊娠前开始产前护理的孕妇进行了回顾性队列研究。从病历中提取疫苗接种日期。比较前指南和后指南队列,以确定在新的 Tdap 指南发布后,Tdap 疫苗接种率和时间是否有所改善。我们还检查了指南前后流感和肺炎球菌疫苗的接种情况。在后指南队列中,使用多变量逻辑回归模型评估了与孕期接受 Tdap 和流感疫苗相关的因素。
在 2294 名合格的个体中,1610 名(70.2%)在指南后队列中接受了治疗。在前指南队列中,47.4%接受了 Tdap,而 Tdap 接种率在指南发布后增加到 86.1%(p<0.001)。同样,在推荐的 27-36 孕周之间接种 Tdap 疫苗的比例从 52.5%增加到 91.8%(p<0.001)。流感疫苗的接种频率显著提高,从 61.2%提高到 72.0%(p<0.001),而肺炎球菌疫苗的接种频率较低且保持不变。产前就诊次数的增加与孕期接受 Tdap 和流感疫苗有关(分别为 aOR 1.09,95%CI 1.05-1.13;aOR 1.50,95%CI 1.17-1.94)。与非西班牙裔白人相比,非西班牙裔黑人在孕期接受 Tdap 和流感疫苗的可能性较小(分别为 aOR 0.51,95%CI 0.33-0.80;aOR 0.68,95%CI 0.48-0.97)。
在实施 2012 年 ACIP 指南后,Tdap 疫苗的接种率和时间有所改善。在研究期间,流感疫苗的接种率也有所提高,而肺炎球菌疫苗的接种率仍然较低。孕妇接种 Tdap 和流感疫苗存在显著的种族差异。